Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer. The Company is developing new drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. One of these agents is an oral immune checkpoint inhibitor that has been through human safety testing where it demonstrated favorable safety and pharmacologic properties. It recently entered cancer clinical trials.

Employee Rating

2.6More
TypePublic
HQBurlingame, US
Founded2014
Size (employees)44 (est)
Websitecorvuspharma.com
Corvus Pharmaceuticals was founded in 2014 and is headquartered in Burlingame, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Corvus Pharmaceuticals

Board of Directors

Board of Directors

Ian T. Clark

Corvus Pharmaceuticals Office Locations

Corvus Pharmaceuticals has an office in Burlingame
Burlingame, (HQ)
102 863 Mitten Rd
Show all (1)
Report incorrect company information

Corvus Pharmaceuticals Financials and Metrics

Corvus Pharmaceuticals Revenue

USD

Net income (Q2, 2018)

(25.9m)

EBIT (Q2, 2018)

(26.9m)

Market capitalization (4-Dec-2018)

175.1m

Closing stock price (4-Dec-2018)

6.0

Cash (30-Jun-2018)

28.1m
Corvus Pharmaceuticals's current market capitalization is $175.1 m.
Annual
USDFY, 2016FY, 2017

General and administrative expense

7.6m10.2m

R&D expense

29.4m46.3m

Operating expense total

37.0m56.5m

EBIT

(37.0m)(56.5m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

General and administrative expense

1.0m1.7m2.8m2.7m2.8m2.5m5.1m

R&D expense

5.4m7.1m7.7m13.5m12.4m12.1m21.8m

Operating expense total

6.4m8.8m10.5m16.2m15.2m14.6m26.9m

EBIT

(6.4m)(8.8m)(10.5m)(16.2m)(15.2m)(14.6m)(26.9m)
Annual
USDFY, 2016FY, 2017

Cash

5.1m45.1m

Current Assets

136.0m91.2m

PP&E

3.2m2.7m

Total Assets

140.2m94.8m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

4.1m4.3m5.6m10.5m34.1m102.6m28.1m

Current Assets

154.1m153.5m146.0m123.1m111.6m145.2m134.4m

PP&E

2.6m2.8m2.9m3.1m3.0m2.5m2.3m

Total Assets

157.2m156.9m149.8m127.1m115.5m148.7m137.9m
Annual
USDFY, 2016FY, 2017

Net Income

(161.0k)(55.7m)

Depreciation and Amortization

842.0k

Accounts Payable

1.9m1.6m

Cash From Operating Activities

(46.2m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Net Income

(6.3m)(15.0m)(10.3m)(16.0m)(31.0m)(14.3m)(25.9m)

Depreciation and Amortization

106.0k250.0k412.0k219.0k439.0k

Accounts Payable

(193.0k)129.0k2.4m2.4m2.3m45.0k(1.2m)

Cash From Operating Activities

(5.6m)(11.8m)(24.5m)(11.0m)(21.9m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Corvus Pharmaceuticals Operating Metrics

FY, 2016

Patent Applications

11

Patents Licensed

18
Show all operating metrics
Report incorrect company information

Corvus Pharmaceuticals News and Updates

Corvus Pharmaceuticals Announces Updated Results from Ongoing Clinical Studies of Lead Programs, CPI-444 and CPI-006, at SITC 33rd Annual Meeting

CPI-444 demonstrated prolonged survival in patients with refractory renal cell carcinoma both as a monotherapy and in combination with atezolizumab

Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 10, 2018

Event will provide a review of new CPI-444 and CPI-006 data presented at SITC & ESMO

Corvus Pharmaceuticals to Present Data on Lead Programs at the European Society for Medical Oncology (ESMO) 2018 Congress and the Society for Immunotherapy of Cancer (SITC) Annual Meeting

BURLINGAME, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present data from its lead programs,…

Corvus Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

BURLINGAME, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the second quarter ended Ju…
Report incorrect company information

Corvus Pharmaceuticals Company Life and Culture

Report incorrect company information

Corvus Pharmaceuticals Frequently Asked Questions

  • When was Corvus Pharmaceuticals founded?

    Corvus Pharmaceuticals was founded in 2014.

  • Who are Corvus Pharmaceuticals key executives?

    Corvus Pharmaceuticals's key executives are Board of Directors.

  • How many employees does Corvus Pharmaceuticals have?

    Corvus Pharmaceuticals has 44 employees.

  • Who are Corvus Pharmaceuticals competitors?

    Competitors of Corvus Pharmaceuticals include Pharmacyclics, Stemline Therapeutics and Cascadian Therapeutics.

  • Where is Corvus Pharmaceuticals headquarters?

    Corvus Pharmaceuticals headquarters is located at 102 863 Mitten Rd, Burlingame.

  • Where are Corvus Pharmaceuticals offices?

    Corvus Pharmaceuticals has an office in Burlingame.

  • How many offices does Corvus Pharmaceuticals have?

    Corvus Pharmaceuticals has 1 office.